Vorolanib, sunitinib, and axitinib: A comparative study of vascular endothelial growth factor receptor inhibitors and their anti-angiogenic effects.

Autor: Bakri SJ; Department of Ophthalmology, Mayo Clinic, Rochester, Minnesota, United States of America., Lynch J; EyePoint Pharmaceuticals, Inc., Watertown, Massachusetts, United States of America., Howard-Sparks M; EyePoint Pharmaceuticals, Inc., Watertown, Massachusetts, United States of America., Saint-Juste S; Department of Polymer Science and Engineering, University of Massachusetts Amherst, Amherst, Massachusetts, United States of America., Saim S; EyePoint Pharmaceuticals, Inc., Watertown, Massachusetts, United States of America.

Publikováno v: PloS one [PLoS One] 2024 Jun 04; Vol. 19 (6), pp. e0304782. Date of Electronic Publication: 2024 Jun 04 (Print Publication: 2024).

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tyrosine Kinase Inhibitors: The Next Chapter in Reducing Treatment Burden for Exudative Retinal Diseases?

Autor: Ravichandran, Pranesh, Canizela, Cecilia, Sayed, Abrahem, Hussain, Rehan M.

Publikováno v: International Ophthalmology Clinics; Winter2025, Vol. 65 Issue 1, p9-15, 7p

A novel chemical delivery system comprising an ocular sustained release formulation of a 3alpha, 17alpha, 21-trihydroxy-5beta-pregnan-20-one-BIS-5-fluorouracil [correction of flourouracil] codrug.

Autor: Howard-Sparks M; College of Pharmacy, Chandler Medical Center, University of Kentucky, Lexington, Kentucky 40536-0082, USA., Al-Ghananeem AM, Crooks PA, Pearson AP

Publikováno v: Drug development and industrial pharmacy [Drug Dev Ind Pharm] 2007 Jun; Vol. 33 (6), pp. 677-82.

Improving the Use of Drug Combinations Through the Codrug Approach.

Autor: Mannhold, Raimund, Kubinyi, Hugo, Folkers, Gerd, Rautio, Jarkko

Publikováno v: Prodrugs & Targeted Delivery: Towards Better ADME Properties; 2010, p345-383, 38p